Cargando…

Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients

Background: Bisdemethoxycurcumin (BDC) might be an inflammation inhibitor in Alzheimer’s Disease (AD). However, BDC is almost insoluble in water, poorly absorbed by the organism, and degrades rapidly. We thus developed a new nanoformulation of BDC based on H-Ferritin nanocages (BDC-HFn). Methods: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagliardi, Stella, Truffi, Marta, Tinelli, Veronica, Garofalo, Maria, Pandini, Cecilia, Cotta Ramusino, Matteo, Perini, Giulia, Costa, Alfredo, Negri, Sara, Mazzucchelli, Serena, Bonizzi, Arianna, Sitia, Leopoldo, Busacca, Maria, Sevieri, Marta, Mocchi, Michela, Ricciardi, Alessandra, Prosperi, Davide, Corsi, Fabio, Cereda, Cristina, Morasso, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409287/
https://www.ncbi.nlm.nih.gov/pubmed/36012501
http://dx.doi.org/10.3390/ijms23169237
_version_ 1784774814717706240
author Gagliardi, Stella
Truffi, Marta
Tinelli, Veronica
Garofalo, Maria
Pandini, Cecilia
Cotta Ramusino, Matteo
Perini, Giulia
Costa, Alfredo
Negri, Sara
Mazzucchelli, Serena
Bonizzi, Arianna
Sitia, Leopoldo
Busacca, Maria
Sevieri, Marta
Mocchi, Michela
Ricciardi, Alessandra
Prosperi, Davide
Corsi, Fabio
Cereda, Cristina
Morasso, Carlo
author_facet Gagliardi, Stella
Truffi, Marta
Tinelli, Veronica
Garofalo, Maria
Pandini, Cecilia
Cotta Ramusino, Matteo
Perini, Giulia
Costa, Alfredo
Negri, Sara
Mazzucchelli, Serena
Bonizzi, Arianna
Sitia, Leopoldo
Busacca, Maria
Sevieri, Marta
Mocchi, Michela
Ricciardi, Alessandra
Prosperi, Davide
Corsi, Fabio
Cereda, Cristina
Morasso, Carlo
author_sort Gagliardi, Stella
collection PubMed
description Background: Bisdemethoxycurcumin (BDC) might be an inflammation inhibitor in Alzheimer’s Disease (AD). However, BDC is almost insoluble in water, poorly absorbed by the organism, and degrades rapidly. We thus developed a new nanoformulation of BDC based on H-Ferritin nanocages (BDC-HFn). Methods: We tested the BDC-HFn solubility, stability, and ability to cross a blood–brain barrier (BBB) model. We tested the effect of BDC-HFn on AD and control (CTR) PBMCs to evaluate the transcriptomic profile by RNA-seq. Results: We developed a nanoformulation with a diameter of 12 nm to improve the solubility and stability. The comparison of the transcriptomics analyses between AD patients before and after BDC-HFn treatment showed a major number of DEG (2517). The pathway analysis showed that chemokines and macrophages activation differed between AD patients and controls after BDC-HFn treatment. BDC-HFn binds endothelial cells from the cerebral cortex and crosses through a BBB in vitro model. Conclusions: Our data showed how BDC-Hfn could improve the stability of BDC. Significant differences in genes associated with inflammation between the same patients before and after BDC-Hfn treatment have been found. Inflammatory genes that are upregulated between AD and CTR after BDC-HFn treatment are converted and downregulated, suggesting a possible therapeutic approach.
format Online
Article
Text
id pubmed-9409287
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94092872022-08-26 Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients Gagliardi, Stella Truffi, Marta Tinelli, Veronica Garofalo, Maria Pandini, Cecilia Cotta Ramusino, Matteo Perini, Giulia Costa, Alfredo Negri, Sara Mazzucchelli, Serena Bonizzi, Arianna Sitia, Leopoldo Busacca, Maria Sevieri, Marta Mocchi, Michela Ricciardi, Alessandra Prosperi, Davide Corsi, Fabio Cereda, Cristina Morasso, Carlo Int J Mol Sci Article Background: Bisdemethoxycurcumin (BDC) might be an inflammation inhibitor in Alzheimer’s Disease (AD). However, BDC is almost insoluble in water, poorly absorbed by the organism, and degrades rapidly. We thus developed a new nanoformulation of BDC based on H-Ferritin nanocages (BDC-HFn). Methods: We tested the BDC-HFn solubility, stability, and ability to cross a blood–brain barrier (BBB) model. We tested the effect of BDC-HFn on AD and control (CTR) PBMCs to evaluate the transcriptomic profile by RNA-seq. Results: We developed a nanoformulation with a diameter of 12 nm to improve the solubility and stability. The comparison of the transcriptomics analyses between AD patients before and after BDC-HFn treatment showed a major number of DEG (2517). The pathway analysis showed that chemokines and macrophages activation differed between AD patients and controls after BDC-HFn treatment. BDC-HFn binds endothelial cells from the cerebral cortex and crosses through a BBB in vitro model. Conclusions: Our data showed how BDC-Hfn could improve the stability of BDC. Significant differences in genes associated with inflammation between the same patients before and after BDC-Hfn treatment have been found. Inflammatory genes that are upregulated between AD and CTR after BDC-HFn treatment are converted and downregulated, suggesting a possible therapeutic approach. MDPI 2022-08-17 /pmc/articles/PMC9409287/ /pubmed/36012501 http://dx.doi.org/10.3390/ijms23169237 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gagliardi, Stella
Truffi, Marta
Tinelli, Veronica
Garofalo, Maria
Pandini, Cecilia
Cotta Ramusino, Matteo
Perini, Giulia
Costa, Alfredo
Negri, Sara
Mazzucchelli, Serena
Bonizzi, Arianna
Sitia, Leopoldo
Busacca, Maria
Sevieri, Marta
Mocchi, Michela
Ricciardi, Alessandra
Prosperi, Davide
Corsi, Fabio
Cereda, Cristina
Morasso, Carlo
Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients
title Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients
title_full Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients
title_fullStr Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients
title_full_unstemmed Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients
title_short Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer’s Disease Patients
title_sort bisdemethoxycurcumin (bdc)-loaded h-ferritin-nanocages mediate the regulation of inflammation in alzheimer’s disease patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409287/
https://www.ncbi.nlm.nih.gov/pubmed/36012501
http://dx.doi.org/10.3390/ijms23169237
work_keys_str_mv AT gagliardistella bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT truffimarta bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT tinelliveronica bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT garofalomaria bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT pandinicecilia bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT cottaramusinomatteo bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT perinigiulia bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT costaalfredo bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT negrisara bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT mazzucchelliserena bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT bonizziarianna bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT sitialeopoldo bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT busaccamaria bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT sevierimarta bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT mocchimichela bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT ricciardialessandra bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT prosperidavide bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT corsifabio bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT ceredacristina bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients
AT morassocarlo bisdemethoxycurcuminbdcloadedhferritinnanocagesmediatetheregulationofinflammationinalzheimersdiseasepatients